CMA1 is potent prognostic marker and associates with immune infiltration in gastric cancer

References

• Bui QL, Grazziotin-Soares D, Hasiniatsy RE, et al. Metastatic stomach cancer: clinical trials in Asia and in Occident. Bull Cancer. 2018;105:932–943.
   PubMed Web of Science ®Google Scholar
• Arnold M, Moore SP, Hassler S, et al. The burden of stomach cancer in indigenous populations: a systematic review and global assessment. Gut. 2014;63:64–71.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833.
   PubMed Web of Science ®Google Scholar
• Procaccio L, Schirripa M, Fassan M, et al. Immunotherapy in gastrointestinal cancers. Biomed Res Int. 2017;2017:4346576.
   PubMedGoogle Scholar
• Noto JM, Peek RM Jr. The gastric microbiome, its interaction with Helicobacter pylori, and its potential role in the progression to stomach cancer. PLoS Pathog. 2017;13:e1006573.
   PubMed Web of Science ®Google Scholar
• Lote H, Cafferkey C, Chau I. PD-1 and PD-L1 blockade in gastrointestinal malignancie. Cancer Treat Rev. 2015;41:893–903.
   PubMed Web of Science ®Google Scholar
• Davidson M, Okines AF, Starling N. Current and future therapies for advanced gastric cancer. Clin Colorectal Cancer. 2015;14:239–250.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207–212.
   PubMed Web of Science ®Google Scholar
• Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–2471.
   PubMed Web of Science ®Google Scholar
• Ralph C, Elkord E, Burt DJ, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 2010;16:1662–1672.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu H, Shen Z, et al. Tumor-infiltrating neutrophils is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. Ann Surg. 2018;267:311–318.
   PubMed Web of Science ®Google Scholar
• Ammendola M, Leporini C, Marech I, et al. Targeting mast cells tryptase in tumor microenvironment: a potential antiangiogenetic strategy. Biomed Res Int. 2014;2014:1–16.
   Web of Science ®Google Scholar
• Ribatti D. Mast cells as therapeutic target in cancer. Eur J Pharmacol. 2016;5:152–157.
   Google Scholar
• Da Silva EZ, Jamur MC, Oliver C. Mast cell function: a new vision. J Histochem Cytochem. 2014;62:698–738.
   PubMed Web of Science ®Google Scholar
• De Souza Junior DA, Santana AC, da Silva EZ, et al. The role of mast cell specific chymases and tryptases in tumor angiogenesis. Biomed Res Int. 2015;2015:1–13.
   Web of Science ®Google Scholar
• Maciel TT, Moura IC, Hermine O. The role of mast cells in cancers. F1000Prime Rep. 2015;7:09.
   PubMedGoogle Scholar
• Glajcar A, Szpor J, Pacek A, et al. The relationship between breast cancer molecular subtypes and mast cell populations in tumor microenvironment. Virchows Arch. 2017;470:505–515.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9:166–180.
   PubMed Web of Science ®Google Scholar
• Lánczky A, Nagy Á, Bottai G, et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016;160:439–446.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108–e110.
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17:174.
   PubMed Web of Science ®Google Scholar
• Aran D, Sirota M, Butte AJ. Systematic pan-cancer analysis of tumour purity. Nat Commun. 2015;6:8971.
   PubMed Web of Science ®Google Scholar
• Siemers NO, Holloway JL, Chang H, et al. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. PLoS One. 2017;12:e0179726.
   PubMed Web of Science ®Google Scholar
• Danaher P, Warren S, Dennis L, et al. Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer. 2017;5:18.
   PubMed Web of Science ®Google Scholar
• Sousa S, Määttä J. The role of tumour-associated macrophages in bone metastasis. J Bone Oncol. 2016;5:135–138.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–W102.
   PubMed Web of Science ®Google Scholar
• Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun. 2007;7:4.
   PubMedGoogle Scholar
• Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. JCO. 2012;30:2678–2683.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
   PubMed Web of Science ®Google Scholar
• Hersberger M, Thun GA, Imboden M, et al. Association of STR polymorphisms in CMA1 and IL-4 with asthma and atopy: the SAPALDIA cohort. Hum Immunol. 2010;71:1154–1160.
   PubMed Web of Science ®Google Scholar
• Carl-McGrath S, Gräntzdörffer I, Lendeckel U, et al. Angiotensin II-generating enzymes, angiotensin-converting enzyme (ACE) and mast cell chymase (CMA1), in gastric inflammation may be regulated by H. pylori and associated cytokines. Pathology. 2009;41:419–427.
   PubMed Web of Science ®Google Scholar
• Sharma S, Rajan UM, Kumar A, et al. A novel (TG)n(GA)m repeat polymorphism 254 bp downstream of the mast cell chymase (CMA1) gene is associated with atopic asthma and total serum IgE levels. J Hum Genet. 2005;50:276–282.
   PubMed Web of Science ®Google Scholar
• Shikotra A, Ohri CM, Green RH, et al. Mast cell phenotype, TNFα expression and degranulation status in non-small cell lung cancer. Sci Rep. 2016;6:38352.
   PubMed Web of Science ®Google Scholar
• Wang S, Li L, Shi R, et al. Mast cell targeted chimeric toxin can be developed as an adjunctive therapy in colon cancer treatment. Toxins (Basel). 2016;8:e71.
   PubMed Web of Science ®Google Scholar
• Huang YH, Zhu C, Kondo Y, et al. CEACAM regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517:386–390.
   PubMed Web of Science ®Google Scholar